Breaking News, Financial News

Financial Report: Galapagos

Revenues up 21% in the quarter, boosted by AbbVie Payment

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Galapagos   1H Revenues: €77.4 million (+20%) 1H Loss: €5.4 million (loss of €11.3 million 1H12) Comments: R&D division revenues were €49.1 million, up 56% driven by revenue recognition on the upfront payment from AbbVie in the global collaboration on GLPG0634. Services revenues were down 14% to €28.4 million. Results include the closure and relocation of the Basel site activities in 1H12, and the Cangenix acquisition this year....

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters